Posted by Michael Wonder on 21 Sep 2023
Disc Medicine receives FDA fast track designation for MWTX-003 for the treatment of polycythemia vera
20 September 2023 - Disc Medicine today announced that the US FDA has granted fast track designation to MWTX-003 for the treatment of patients with polycythemia vera.
MWTX-003, also known as DISC-3405, is an investigational, anti-TMPRSS6 (Transmembrane Serine Protease 6, also known as Matriptase-2) monoclonal antibody designed to increase hepcidin production and suppress serum iron, that Disc in-licensed from Mabwell Therapeutics in January 2023.
